Research Use Only (RUO). All content on this page describes laboratory and preclinical research findings only. Hexarelin is not approved for human therapeutic use. This information is intended for qualified researchers and laboratory professionals only.
Introduction: Hexarelin Beyond Growth Hormone Research
Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂) is a hexapeptide GHS-R1a agonist with among the highest GHS-R1a binding affinity in its class (Kd ~1 nM vs ~10 nM for ipamorelin). Like GHRP-6, hexarelin produces potent GH release through pituitary GHS-R1a signalling, but is distinguished from other GH secretagogues by its high-affinity binding to CD36 — a multiligand scavenger receptor expressed on macrophages, adipocytes, cardiomyocytes, and vascular endothelium. CD36 binding provides hexarelin with a GH-independent direct mechanism relevant to lipid metabolism, atherosclerosis biology, adipogenesis, and cardiovascular research. In metabolic syndrome — characterised by abdominal obesity, dyslipidaemia (elevated TG, low HDL-C), hypertension, and insulin resistance — both the GH axis and CD36 biology are mechanistically relevant, positioning hexarelin as a multi-pathway research tool for metabolic disease research.
🔗 Related Reading: For a comprehensive overview of Hexarelin research, mechanisms, UK sourcing, and cardiac biology, see our Hexarelin UK Complete Research Guide 2026.
CD36 Biology: Lipid Uptake, Atherosclerosis and Foam Cell Formation
CD36 (also known as FAT/SR-B2) is a class B scavenger receptor that binds oxidised LDL (oxLDL), long-chain fatty acids (LCFA), thrombospondin-1, and collagen. In macrophages, CD36-mediated oxLDL uptake drives foam cell formation — the early pathological lesion of atherosclerosis: macrophages engulf cholesterol-rich oxLDL particles through CD36, converting to lipid-laden foam cells that accumulate in the subintimal space, forming fatty streaks that progress to atherosclerotic plaques. CD36 on adipocytes facilitates LCFA uptake from plasma into adipose tissue — contributing to fat storage and adipose expansion in obesity. On cardiomyocytes, CD36-mediated LCFA uptake provides fatty acid substrate for the heart’s dominant fuel source under fasting conditions.
Hexarelin’s CD36 agonism — an activity not shared by ipamorelin, sermorelin, or CJC-1295 — means hexarelin directly engages lipid biology through a GH-independent mechanism. Published research demonstrates hexarelin-CD36 interaction inhibits macrophage foam cell formation: hexarelin reduces CD36-dependent oxLDL uptake in macrophages through receptor internalisation/downregulation after hexarelin-CD36 binding, and through downstream signalling that reduces CD36 expression. Research in apolipoprotein E knockout (ApoE KO) atherosclerosis mouse models tests hexarelin effects on plaque burden: aortic en face Oil Red O lesion area, plaque histology (necrotic core, cap thickness, macrophage/smooth muscle content), and inflammatory cytokine profile in plaque tissue (TNF-α, IL-1β, MCP-1 by IHC).
Visceral Adiposity and Hexarelin Research
Metabolic syndrome is characterised by central (visceral) adiposity — enlargement of intra-abdominal fat depots (mesenteric, omental, retroperitoneal) that are more metabolically active, more inflammatory, and more lipolytically responsive than subcutaneous fat. Visceral adipocytes express CD36 and GHS-R1a, providing dual receptor targets for hexarelin in adipose biology.
GH axis restoration through hexarelin GHS-R1a agonism specifically targets visceral fat: GH directly stimulates β₃-adrenergic receptor-mediated lipolysis in visceral adipocytes, reducing VAT mass. Visceral fat is also a major source of free fatty acid (FFA) flux to the portal vein — elevated portal FFA drives hepatic insulin resistance (by increasing hepatic gluconeogenesis and VLDL-TG secretion) and hepatic steatosis. Research examining hexarelin effects on visceral adiposity in metabolic syndrome models (Zucker fatty rats, HFD-obese mice, ob/ob mice) measures: CT-measured VAT area; adipose depot weights (gonadal, mesenteric, retroperitoneal fat separately); adipocyte size distribution (H&E histology, image analysis); adipose lipolysis (glycerol and NEFA release from ex vivo fat pad incubations); and FFA portal vein concentration (portal blood sampling in surgical preparation).
Dyslipidaemia Research: TG, HDL-C, and Hepatic Lipid Metabolism
Metabolic syndrome dyslipidaemia is characterised by hypertriglyceridaemia (elevated VLDL-TG), low HDL-C, and small dense LDL particles — all driven by hepatic lipid metabolism dysregulation and insulin resistance. GH has well-established pro-lipolytic and anti-lipogenic effects in liver: GH activates hepatic ATGL (adipose triglyceride lipase, encoded by Pnpla2) and reduces VLDL-TG secretion by increasing LPL (lipoprotein lipase) activity in peripheral tissues. Hexarelin’s GH-releasing mechanism therefore reduces circulating TG through enhanced peripheral TG clearance and reduced hepatic TG production.
CD36 in hepatocytes mediates LCFA uptake contributing to hepatic fat accumulation in NASH/MASLD. Hexarelin-CD36 interaction may reduce hepatic CD36 expression (through receptor downregulation), reducing hepatic fatty acid influx and hepatic steatosis. Research endpoints for hexarelin dyslipidaemia biology: plasma TG, total cholesterol, HDL-C, LDL-C (enzymatic photometric assay); VLDL-TG production rate (Triton WR-1339 LPL inhibitor injection protocol, serial plasma TG measurements); hepatic TG content (Folch extraction); hepatic LCFA uptake (fluorescently labelled fatty acid [BODIPY C16] liver accumulation); CD36 protein in liver (Western blot, IHC); and LPL activity in post-heparin plasma (heparin-releasable LPL).
Insulin Resistance: GH Axis and Direct Receptor Contributions
GH has complex effects on insulin sensitivity: acute supraphysiological GH is insulin-antagonistic through JAK2-STAT5-driven suppression of IRS-1 (through SOCS proteins — suppressors of cytokine signalling — that are STAT5 targets competing with IRS-1 for JAK2 binding, thereby reducing IRS-1 activation and downstream PI3K/Akt/GLUT4 signalling). However, the IGF-1 generated downstream of chronic GH elevation is insulin-sensitising through IGF-1R/IRS-1/PI3K/Akt/GLUT4 pathway. In somatopause research, restoring physiological (rather than supraphysiological) GH pulsatility with hexarelin or ipamorelin produces net insulin sensitisation through IGF-1-mediated effects dominating over the direct GH insulin-antagonistic mechanism.
CD36 in skeletal muscle contributes to fatty acid uptake for β-oxidation fuel — an important energy source during exercise. In insulin-resistant states, CD36-mediated excess LCFA accumulation in muscle generates ceramide and DAG lipid intermediates that activate PKCθ and PP2A, reducing IRS-1 tyrosine phosphorylation and impairing insulin-stimulated GLUT4 translocation. Hexarelin-CD36 interaction’s effect on muscle lipid accumulation provides a research question for whether hexarelin can reduce muscle ceramide/DAG-driven insulin resistance through CD36 modulation. Research endpoints: muscle ceramide (LC-MS/MS lipidomics); muscle DAG species; IRS-1 serine phosphorylation (insulin resistance marker, S307 mouse); Akt/GLUT4 insulin signalling in muscle; and muscle insulin-stimulated glucose uptake (²H-deoxyglucose method).
🔗 Also See: For Hexarelin and cardiac research deep-dive, see our Hexarelin and Cardiac Research UK 2026.
Hypertension and Vascular Biology in Metabolic Syndrome
Metabolic syndrome hypertension arises from multiple mechanisms: RAAS activation by visceral adipose (adipose renin-angiotensin system), increased sympathetic nervous system tone (insulin resistance activating hypothalamic-sympathetic circuits), endothelial dysfunction (reduced eNOS-derived NO from oxidative stress and FFA-mediated eNOS uncoupling), and structural vascular remodelling (VSMC hypertrophy from elevated angiotensin II and endothelin-1). GH/IGF-1 restoration through hexarelin may address hypertension through IGF-1-mediated eNOS activation (Akt-eNOS Ser1177 phosphorylation) and reduced VSMC remodelling. CD36-mediated effects on vascular biology — particularly thrombospondin-1 signalling (a CD36 ligand that suppresses eNOS activity through CD36-src kinase-eNOS inhibition) — provide additional hexarelin vascular research angles.
Research endpoints for hexarelin vascular biology in metabolic syndrome: tail-cuff blood pressure (conscious, trained mice) or carotid arterial catheter pressure (anaesthetised); aortic ring relaxation curves (acetylcholine endothelium-dependent vs sodium nitroprusside endothelium-independent relaxation — eNOS function); plasma endothelin-1 and angiotensin II ELISA; aortic eNOS/phospho-eNOS IHC; and 3-nitrotyrosine (eNOS uncoupling marker from peroxynitrite) in aortic tissue.
Research Endpoint Summary
A comprehensive hexarelin metabolic syndrome research endpoint panel includes: plasma TG/cholesterol/HDL-C/LDL-C; VLDL-TG production rate; hepatic TG (Folch)/CD36 expression; EchoMRI fat mass/lean mass; CT VAT area; adipocyte size distribution; adipose depot weights; plasma GH/IGF-1/HOMA-IR; OGTT; muscle ceramide/DAG lipidomics; muscle IRS-1 S307 phosphorylation; ApoE KO aortic plaque area/foam cell histology; macrophage oxLDL uptake; blood pressure (tail-cuff/catheter); aortic ring eNOS vasodilation; endothelin-1/angiotensin II; and CD36-selective antagonist (sulfo-N-succinimidyl oleate [SSO] or JC5) arms to dissect GHS-R1a vs CD36-mediated hexarelin effects.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Hexarelin for research and laboratory use. View UK stock →
Summary
Hexarelin engages metabolic syndrome biology through dual receptor mechanisms: GHS-R1a agonism restoring GH pulsatility with downstream visceral fat lipolysis, IGF-1 insulin sensitisation, and dyslipidaemia correction; and CD36 agonism directly modulating macrophage foam cell formation, hepatic and muscle lipid accumulation, and vascular thrombospondin-eNOS biology. ApoE KO atherosclerosis models, DIO metabolic syndrome mice, and ZDF rats provide validated research platforms. SSO CD36-selective antagonist control arms allow dissection of GHS-R1a vs CD36-mediated hexarelin metabolic syndrome effects — a unique mechanistic research advantage that distinguishes hexarelin from other GH secretagogue research compounds.
Research Use Only. Not for human therapeutic administration. All research must comply with applicable institutional and regulatory requirements.
